{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:16:38Z","timestamp":1774008998508,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background\/Objectives: Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease with increasing global prevalence. However, data on this disease from Central Asia are lacking. We aimed to describe the clinical, serological, and treatment characteristics of PBC patients in Kazakhstan. Methods: This study was a multicenter, retrospective, observational study including adults diagnosed with PBC between 2014 and 2022 across seven hepatology centers in Kazakhstan. Clinical presentation, laboratory parameters, autoimmune comorbidities, liver disease severity, and ursodeoxycholic acid (UDCA) treatment response were assessed. Biochemical response at 1 year was evaluated using Paris-1 and Barcelona criteria. Results: A total of 230 patients were included; 93.9% were female and 91.3% were of Asian ethnicity, with a median age at diagnosis of 53 years. Cirrhosis was present at diagnosis in 50.2% of the patients. PBC with autoimmune hepatitis (AIH) features was identified in 56.1% of the patients and was associated with higher rates of cirrhosis, portal hypertension complications, antinuclear antibody (ANA) positivity, and higher elastography indices compared with isolated PBC. Overall, approximately 55% of the patients achieved a biochemical response to UDCA at 1 year, with similar response rates between patients with PBC and those with PBC with AIH features. Conclusions: This first comprehensive study of PBC in Kazakhstan demonstrates late disease presentation with a high burden of cirrhosis and frequent AIH features. Despite advanced disease, about half of the patients achieved biochemical remission on UDCA. These findings underscore the need for earlier diagnosis and optimized management strategies for PBC in Kazakhstan and similar settings in Central Asia.<\/jats:p>","DOI":"10.3390\/diseases14030112","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:44:41Z","timestamp":1773999881000},"page":"112","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Demographic Features of Primary Biliary Cholangitis in Kazakhstan"],"prefix":"10.3390","volume":"14","author":[{"given":"Aisulu","family":"Gainutdin","sequence":"first","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-3966","authenticated-orcid":false,"given":"Alexander","family":"Nersesov","sequence":"additional","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komori","family":"Atsumasa","sequence":"additional","affiliation":[{"name":"NHO Nagasaki Medical Center, Nagasaki 856-8562 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aigul","family":"Raissova","sequence":"additional","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saltanat","family":"Madenova","sequence":"additional","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Yerdaliyeva","sequence":"additional","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinara","family":"Suleimenova","sequence":"additional","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balday","family":"Issenova","sequence":"additional","affiliation":[{"name":"Asfendiyarov Kazakh National Medical University, Almaty 05000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: Epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tan, J.J., Chung, A.H., Loo, J.H., Quek, J.W.E., Sharma, S., Singh, C.L., Yap, R.X.J., Tay, W.X., Smith, M.K., and Lytvyak, E. (2025). Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol., epub ahead of print.","DOI":"10.1136\/gutjnl-2025-IDDF.173"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9151525","DOI":"10.1155\/2021\/9151525","article-title":"The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis","volume":"2021","author":"Gazda","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5009\/gnl16365","article-title":"Extrahepatic Manifestations of Primary Biliary Cholangitis","volume":"11","author":"Chalifoux","year":"2017","journal-title":"Gut Liver"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101132","DOI":"10.1016\/j.jhepr.2024.101132","article-title":"Incidence and prevalence of primary biliary cholangitis in the Netherlands\u2014A nationwide cohort study","volume":"6","author":"Werner","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1038\/s41598-019-47890-2","article-title":"Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort","volume":"9","author":"Marschall","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e931786","DOI":"10.12659\/AOT.931786","article-title":"Liver Transplantation: A 10-Year Low-Volume Transplant Center Experience in Kazakhstan","volume":"26","author":"Saparbay","year":"2021","journal-title":"Ann. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jhep.2008.11.029","article-title":"Opisthorchiasis mimicking primary biliary cirrhosis as an indication for liver transplantation","volume":"50","author":"Melling","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_10","first-page":"559","article-title":"Bone Marrow and Peripheral Blood Mononuclear Cell Phenotype Changes after Cultivation and Autologous Infusion in Patients with Primary Biliary Cholangitis","volume":"49","author":"Saipiyeva","year":"2024","journal-title":"Iran. J. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1038\/s41598-024-60086-7","article-title":"Evaluation of liver transplantation services in Kazakhstan from 2012 to 2023","volume":"14","author":"Semenova","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_12","first-page":"119","article-title":"Primary Biliary Cholangitis with Associated Raynaud Syndrome Treatment Outcome: A Case Report","volume":"22","author":"Doszhan","year":"2025","journal-title":"J. Clin. Med. Kaz."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: Epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/MEG.0000000000001234","article-title":"Association of smoking with liver fibrosis and mortality in primary biliary cholangitis","volume":"30","author":"Mantaka","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/MEG.0000000000001100","article-title":"Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients","volume":"30","author":"Zhang","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Freedman, B.L., Danford, C.J., Patwardhan, V., and Bonder, A. (2020). Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051449"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.14740\/jmc3623","article-title":"Primary Biliary Cholangitis Overlap With Autoimmune Hepatitis? A Case Report","volume":"12","author":"Costa","year":"2021","journal-title":"J. Med. Cases."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13256-023-03932-y","article-title":"Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis complicated with atypical hepatocellular carcinoma: A case report","volume":"17","author":"Caraiani","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"ref_21","first-page":"e51630","article-title":"Chronic Liver Disease, Not Everything Is What It Seems: Autoimmune Hepatitis\/Primary Biliary Cholangitis Overlap Syndrome","volume":"16","author":"Pereira","year":"2024","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/tgh-24-140","article-title":"Overlap syndromes in autoimmune liver disease: A review","volume":"10","author":"Sohal","year":"2025","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4254\/wjh.v16.i9.1269","article-title":"Predictors of survival in autoimmune liver disease overlap syndromes","volume":"16","author":"Jayabalan","year":"2024","journal-title":"World J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Angelara, M., Papachristou, K., Papatheodoridi, M., Nasiri-Ansari, N., Karagiannakis, D.S., and Androutsakos, T. (2025). Primary biliary cholangitis. Treatment options in 2025. A narrative review. Front Immunol., 16.","DOI":"10.3389\/fimmu.2025.1698833"},{"key":"ref_25","first-page":"736","article-title":"Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12072-022-10431-7","article-title":"Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: An early criterion","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8829510","DOI":"10.1155\/2021\/8829510","article-title":"Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis","volume":"2021","author":"Gao","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/3\/112\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:15:15Z","timestamp":1774001715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/3\/112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["diseases14030112"],"URL":"https:\/\/doi.org\/10.3390\/diseases14030112","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}